Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2023. Read More.
Open Access Percentage
62%
Total
Publications
784
Total Open
Publications
489
Total
Citations
64K
Open Access
Percentage
62%
Total
Publications
784
Total Open
Publications
489
Total
Citations
64K
Breakdown
Publisher Open
17%
Both
35%
Other Platform Open
10%
Closed
38%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 29%
120
Hybrid 33%
135
No Guarantees 38%
154
Other Platform Open
Domain 82%
290
Institution 25%
87
Preprint 14%
51
Public 9%
30
Other Internet 9%
30
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 288 |
Europe PMC | Domain | 179 |
bioRxiv | Preprint | 26 |
University College London - UCL Discovery | Institution | 23 |
Semantic Scholar | Public | 22 |
medRxiv | Preprint | 14 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 14 |
DOI | Other Internet | 14 |
Figshare | Public | 13 |
Research Square | Preprint | 11 |